The US Food and Drug Administration (FDA) has granted accelerated approval to a novel therapy for advanced melanoma, called Tudriqev, which is an oncolytic virus therapy that targets cancer cells by using a trained herpes simplex virus to multiply in melanoma cells. This therapy is approved as part of a combination therapy, where patients also take a standard immunotherapy infusion to strengthen the immune response against cancer cells.
Key Insights
Tudriqev is an oncolytic virus therapy that targets cancer cells using a trained herpes simplex virus. The therapy is approved for adult patients with advanced melanoma that cannot be removed completely with surgery and is not responding to standard immunotherapy. The approval marks a major milestone for patients with limited options when standard immunotherapy stops working.
